Serum glycan signatures of gastric cancer

Abstract

Glycomics, a comprehensive study of glycans expressed in biological systems, is emerging as a simple yet highly sensitive diagnostic tool for disease onset and progression. This study aimed to use glycomics to investigate glycan markers that would differentiate patients with gastric cancer (GC) from those with non-atrophic gastritis (NAG). Patients with duodenal ulcer (DU) were also included because they are thought to represent a biologically different response to infection with Helicobacter pylori, a bacterial infection that can cause either GC or DU. We collected 72 serum samples from patients in Mexico City that presented with NAG, DU, or GC. N-glycans were released from serum samples using the generic method with PNGase F and were analyzed by MALDI FT-ICR MS. The corresponding glycan compositions were calculated based on accurate mass. ANOVA based statistical analysis was performed to identify potential markers for each sub-group. Nineteen glycans were significantly different among the diagnostic groups. Generally, decreased levels of high-mannose type glycans, glycans with one complex type antenna, bigalactosylated biantennary glycans, and increased levels of non-galactosylated biantennary glycans were observed in gastric cancer cases. Altered levels of serum glycans were also observed in DU, but differences were generally in the same direction as GC. Serum glycan profiles may provide biomarkers to differentiate GC cases from controls with NAG. Further studies will be needed to validate these findings as biomarkers and identify the role of protein glycosylation in GC pathology.